RET Clinical Research Trials

featured

S1900B: A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent

0 views
31 Mar, 2021
1 location

featured

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

356 views
08 Nov, 2020
2 locations

Safety Efficacy and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

This study will be conducted to assess the safety and tolerability of BOS172738 when administered to patients with advanced solid tumors with rearranged during transfection (RET) gene

33 views
05 Mar, 2021
29 locations

Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)

(VEGFR1-3), RET, AXL, FLT3 and KIT. Cabozantinib has been approved by the FDA for clinical treatment of progressive, metastatic medullary thyroid cancer. Recently published trials have demonstrated

bladder cancer

serum pregnancy test

platinum-based chemotherapy

hysterectomy

carcinoma

46 views
26 Jan, 2021
12 locations

Effectiveness of Regenerative Endodontics Therapy for Single-rooted Mature Permanent Tooth With Pulp Necrosis

This study is to evaluate the effectiveness of regenerative endodontics therapy in single-rooted permanent teeth with pulp necrosisand compare the clinical efficacy of platelet rich fibrin (PRF) and blood clot (BC) as scaffolds.

fibrin

blood clot

root canal therapy

clot

0 views
24 Jan, 2021
3 locations

Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure

The primary objective is to compare the efficacy of lenvatinib plus Best Supportive Care versus Placebo plus Best Supportive Care in the treatment of patients with advanced GIST, after failure of imatinib and sunitinib.

0 views
26 Jan, 2021
7 locations

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, improves outcome when compared to a platinum

chemoradiotherapy

pemetrexed

carboplatin

cancer chemotherapy

platinum-based chemotherapy

27 views
08 May, 2021
82 locations

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant

measurable disease

vandetanib

renal function

cabozantinib

electrolytes

15 views
09 May, 2021
212 locations

A Study of LOXO-292 in Participants With Advanced Solid Tumors RET Fusion-Positive Solid Tumors and Medullary Thyroid Cancer

) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation

measurable disease

ret inhibitor

cfdna

renal function

kidney function test

1244 views
09 May, 2021
159 locations

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

The reason for this study is to see if the study drug selpercatinib compared to a standard treatment is effective and safe in participants with rearranged during transfection (RET) fusion

squamous non-small cell lung cancer